Eam Investors, LLC Neurocrine Biosciences Inc Transaction History

Eam Investors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $17,715 - $21,091	-166 Reduced 1.24%	13,187 $1.58 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $187,833 - $220,040	2,041 Added 18.04%	13,353 $1.42 Million
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $857,336 - $1.13 Million	11,312 New	11,312 $1.1 Million
Q2 2018 Aug 03, 2018	SELL	$75.3 - $105.99 $3.13 Million - $4.4 Million	-41,529 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$75.88 - $92.43 $246,534 - $300,305	3,249 Added 8.49%	41,529 $3.44 Million
Q4 2017 Feb 12, 2018	SELL	$58.53 - $77.59 $28,855 - $38,251	-493 Reduced 1.27%	38,280 $2.97 Million
Q3 2017 Nov 08, 2017	BUY	$47.97 - $61.28 $1.86 Million - $2.38 Million	38,773	38,773 $2.38 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.